

CONTENTS

Preface	xix
1.1 From Gene to Product: The Advantage of Integrative Biotechnology	1
<i>Frank-Ranier Schmidt</i>	
1.2 Sequencing the Human Genome: Was It Worth It?	53
<i>Eugene Zabarovsky</i>	
1.3 Overview: Differentiating Issues in the Development of Macromolecules Compared with Small Molecules	89
<i>Günther Blaich, Bernd Janssen, Gregory Roth, and Jochen Salfeld</i>	
1.4 Integrated Development of Glycobiologics: From Discovery to Applications in the Design of Nanoparticulate Drug Delivery Systems	125
<i>Christine Vauthier, Isabelle Bertholon, and Denis Labarre</i>	
1.5 R&D Paradigm Shift and Billion-Dollar Biologics	161
<i>Krishan Maggon</i>	
2 From Defining Bioinformatics and Pharmacogenomics to Developing Information-Based Medicine and Pharmacotyping in Health Care	201
<i>Ioannis S. Vizirianakis</i>	
3.1 Toxicogenomics	229
<i>Mary Jane Cunningham and Mrinal Shah</i>	
	xiii

3.2	Preclinical Pharmacokinetics	253
	<i>Donald E. Mager and Murali Ramanathan</i>	
3.3	Strategies for the Cytosolic Delivery of Macromolecules: An Overview	279
	<i>Aravind Asokan, Roland Cheung, and Moo J. Cho</i>	
4.1	Basic Issues in the Manufacture of Macromolecules	297
	<i>Corinne Lengsfeld and Thomas Anchordoquy</i>	
4.2	Process Validation for Biopharmaceuticals	319
	<i>Beth Junker</i>	
4.3	Stability Assessment and Formulation Characterization	371
	<i>Albert H.L. Chow, Henry H.Y. Tong, and Ying Zheng</i>	
4.4	Protein Posttranslational Modification: A Potential Target in Pharmaceutical Development	417
	<i>M.D. Mostaqul Huq and Li-Na Wei</i>	
4.5	PEGylation: Camouflage of Proteins, Cells, and Nanoparticles Against Recognition by the Body's Defense Mechanism	443
	<i>Yong Woo Cho, Jae Hyung Park, Ji Sun Park, and Kinam Park</i>	
4.6	Unexpected Benefits of a Formulation: Case Study with Erythropoietin	463
	<i>David Keast</i>	
5.1	Capillary Separation Techniques	469
	<i>Dong Hee Na and Kang Choon Lee</i>	
5.2	Pharmaceutical Bioassay	511
	<i>Jun Li, Ming Zhao, and Shiqi Peng</i>	
5.3	Analytical Considerations for Immunoassays for Macromolecules	573
	<i>Marian Kelley and Binodh DeSilva</i>	
5.4	Chromatography-Based Separation of Proteins, Peptides, and Amino Acids	585
	<i>Jan Moebius, Remco Swart, and Albert Sickman</i>	
5.5	Bioanalytical Method Validation for Macromolecules	611
	<i>Gerhard K.E. Scriba</i>	
5.6	Microarrays in Drug Discovery and Development	633
	<i>Krishnanand D. Kumble and Sarita Kumble</i>	

5.7 Genetic Markers and Genotyping Analyses for Genetic Disease Studies	661
<i>Anne E. Kwitek and Michael Olivier</i>	
6.1 Proteins: Hormones, Enzymes, and Monoclonal Antibodies—Background	691
<i>Wayne Materi, Zoltan Gombos, and David S. Wishart</i>	
6.2 Formulation and Delivery Issues of Therapeutic Proteins	737
<i>Sathy V. Balu-Iyer, Razvan D. Miclea, and Vivek S. Purohit</i>	
6.3 Pharmacokinetics	757
<i>Nobuhito Shibata, Yukato Ito, and Kanji Takada</i>	
6.4 Immunogenicity of Therapeutic Proteins	815
<i>Suzanne Hermeling, Daan J.A. Crommelin, Huub Schellekens, and Wim Jiskoot</i>	
6.5 Development and Characterization of High-Affinity Anti-Topotecan IgG and Fab Fragments	835
<i>Jin Chen and Joseph P. Balthasar</i>	
6.6 Recombinant Antibodies for Pathogen Detection and Immunotherapy	851
<i>Nicholas J. Pokorny, Jeanine I. Boulter-Bitzer, J. Chris Hall, Jack T. Trevors, and Hung Lee</i>	
6.7 The Radiopharmaceutical Science of Monoclonal Antibodies and Peptides for Imaging and Targeted <i>in situ</i> Radiotherapy of Malignancies	883
<i>Raymond M. Reilly</i>	
7.1 Gene Therapy—Basic Principles and the Road from Bench to Bedside	943
<i>Gabor M. Rubanyi</i>	
7.2 Plasmid DNA and Messenger RNA for Therapy	971
<i>Steve Pascolo</i>	
7.3 Formulations and Delivery Limitations of Nucleic-Acid-Based Therapies	1013
<i>Tatiana Segura</i>	
7.4 Pharmacokinetics of Nucleic-Acid-Based Therapeutics	1061
<i>John C. Schmitz, Aleksandra Pandyra, James Koropatnick, and Randal. W. Berg</i>	

7.5	Case Studies—Development of Oligonucleotides	1087
	<i>Ezharul Hoque Chowdhury and Toshihiro Akaike</i>	
7.6	RNA Interference: The Next Gene-Targeted Medicine	1109
	<i>Andrew V. Oleinikov and Matthew D. Gray</i>	
7.7	Delivery Systems for Peptides/Oligonucleotides and Lipophilic Nucleoside Analogs	1149
	<i>R.A. Schwendener and Herbert Schott</i>	
8.1	Growth Factors and Cytokines	1173
	<i>Mandeep K. Mann and Brian E. Cairns</i>	
8.2	Growth Factors, Cytokines, and Chemokines: Formulation, Delivery, and Pharmacokinetics	1197
	<i>Heping Cao and Rui Lin</i>	
9	Protein Engineering with Noncoded Amino Acids: Applications to Hirudin	1225
	<i>Vincenzo De Filippis</i>	
10.1	Production and Purification of Adenovirus Vectors for Gene Therapy	1261
	<i>D.M.F. Prazeres and J.A.L. Santos</i>	
10.2	Assessing Gene Therapy by Molecular Imaging	1297
	<i>Pascal Delepine and Claude Férec</i>	
11	Overview of Stem and Artificial Cells	1313
	<i>Alejandro Soto-Gutierrez, Nalu Navarro-Alvarez, Jorge David Rivas-Carrillo, and Naoya Kobayashi</i>	
12.1	Regulation of Small-Molecule Drugs Versus Biologicals Versus Biotech Products	1373
	<i>María de los Angeles Cortés Castillo and José Luis Di Fabio</i>	
12.2	Intellectual Property and Biotechnology	1391
	<i>Tania Bubela and Karen Lynne Durell</i>	
12.3	Comparability Studies for Later-Generation Products—Plant-Made Pharmaceuticals	1433
	<i>Patrick A. Stewart</i>	
12.4	Biosimilars	1453
	<i>H. Schellekens, W. Jiskoot, and D.J.A. Crommelin</i>	

13.1 The Promise of Individualized Therapy	1463
<i>Michael Oettel</i>	
13.2 Enhanced Proteomic Analysis by HPLC Prefractionation	1491
<i>Pierre C. Havugimana, Peter Wong, and Andrew Emili</i>	
13.3 An Overview of Metabonomics Techniques and Applications	1503
<i>John C. Lindon</i>	
13.4 Bioterrorism	1525
<i>Dany Shoham</i>	
Index	1653

